Herantis Pharma Plc.

Listen to Herantis Pharma Plc.’ CEO, Antti Vuolanto’s presentation at inderesTV, December 2 at 4:00 pm EET Watch the presentation https://lnkd.in/edsBCABR #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology

CEO Antti Vuolanto presented Herantis Pharma Plc. at BioStock Life Science Summit 2024. Watch the presentation https://lnkd.in/d8zxiGSm #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology #Biostock

Meet Herantis Pharma Plc.’ CEO, Antti Vuolanto and CFO, Tone Kvåle at the seventh annual BioStock Life Science Summit, Lund, Sweden from November 20 to 21, 2024. CEO, Antti Vuolanto will give a company presentation, November 20, at 11:20 CET. #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology #Biostock

Herantis Pharma Plc. has successfully completed the Part 1 of the Phase 1b clinical trial. Read more: https://lnkd.in/d9pJz4-C #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology

Its almost time for BioStock Life Science Summit 2024! 👏 ✒ 🗓 Have you signed up? If not, do so TODAY at https://lnkd.in/evGSkHq9 🗓 🖋 🌟 The program is jam-packed with company showcases and thought-provoking insights from industry leaders and expert investors! Three companies that will take the stage to present their groundbreaking work are LIPUM AB, Herantis Pharma Plc. and Vesper Bio. 🌟 Ping Ola Sandborgh, Antti Vuolanto and Lovisa Sunesson 😎

Meet Herantis Pharma Plc.’ CEO, Antti Vuolanto and CSO, Henri Huttunen at BIO-Europe in Stockholm, Sweden from November 4 to 6, 2024.   #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology

Key messages from today’s R&D webinar Herantis Pharma Plc.’s R&D webinar will take place today, October 23, 2024 (10:00-11:00 EEST/9:00-10:00 CEST). Link to the R&D webinar: https://lnkd.in/dpjNBQwV   Herantis’ key messages: • HER-096 shows preclinical evidence of being neurorestorative not just slowing, but also reversing neuronal damage for symptomatic improvement. • HER-096 is administered by a patient-friendly, subcutaneous injections. • Subcutaneous single dose injections of HER-096 had overall good safety and tolerability profile in healthy subjects in the Phase 1a clinical trial. • Biomarker research program ongoing, with the goal to identify treatment response/pharmacodynamic biomarkers. • Significant milestones going forward. • Strong external validation of Herantis’ HER-096 program. Read more: https://lnkd.in/eaVYiXma

Meet Herantis Pharma Plc.’ CEO, Antti Vuolanto at BIO-Europe in Stockholm, Sweden from November 4 to 6, 2024. Herantis is also selected for an in-person company presentation during the CNS/Neurology session, November 4, at 13:15 CET in room K18.   Join us there! Read more about the event: https://lnkd.in/dnuNZ2D #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology #BIOEurope

We are pleased to share another great session from the 24th Annual Biotech in Europe Forum. Neurological Disorders Panel: Rapid Advances with New Targets & Modalities from the 24th Annual #Sachs_BEF. Chaired by: Keld Flintholm Jørgensen, SVP & CBO, H. Lundbeck A/S Panellists: Antti Vuolanto, CEO, Herantis Pharma Plc. Carlos Buesa, Founder & CEO, Oryzon Genomics SA Federico Bolognani, MD, PhD, Chief Medical Officer, IAMA Therapeutics S.r.l. Lynn A Durham, Founder & CEO, STALICLA SA Rupert H., CEO, Avata Biosciences To view now, please click here: https://lnkd.in/dv8r3yfP #Neuroscience #NeurologyAdvances #MedicalResearch #Biotech #GeneTherapy #PersonalizedMedicine #SALSW

Herantis Pharma Plc. is pleased to announce start of HER-096 dosing in the Phase 1b trial.   The primary objective of the Phase 1b trial is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson’s disease.  Read more: https://lnkd.in/dMM_v_jm #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology